Join ERT and Helen Lundblad, PRO Manager from AstraZeneca, to explore paper vs. electronic collection. Electronic collection of clinical trial data has been recommended by the FDA since 2009 . While error-prone paper diaries introduce unnecessary risks into your study, using electronic Clinical Outcome Assessments (eCOA) has been shown to better engage patients, improve data quality and accelerate trials.
Key takeaways include:
- Understanding when to use paper or electronic data collection in your next clinical trial
- Understanding the benefits of eCOA in relation to data quality, cost, regulatory requirements, patient safety and engagement as well as study performance and timelines
- Exploring the myths and truths behind the statement: “Implementing eCOA is more expensive and cumbersome than paper”
- Getting perspective and insights from a global sponsor’s Patient Reported Outcome Manager on the topic
Take advantage of technology and science to engage patients for real-time insights and data quality that give confidence in the results you submit to regulators.